94 terminated. 94 Phase 3, 17 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 94 | Terminated 94 |
| Phase 2 | 17 | Terminated 17 |
Follow Colonic Diseases: new trials by email Literature Review of Colonic Diseases trials Research Report on Colonic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma Best Supportive Care, Balstilimab, Botensilimab - Colorectal Cancer | Phase 3 | Terminated | Canadian Cancer Trials Group | 21 | 2026-03-31 | 2026-07-16 |
| Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio AVT16, Vedolizumab - Ulcerative Colitis | Phase 3 | Terminated | Alvotech Swiss AG | 301 | 2024-09-23 | 2025-12-26 |
| A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) Ozanimod, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Bristol-Myers Squibb | 131 | 2022-12-09 | 2025-03-26 |
| A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission Filgotinib, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 22 | 2022-07-26 | 2024-10-04 |
| A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer Nivolumab-relatlimab FDC, Regorafenib, TAS-102 - Colorectal Neoplasms | Phase 3 | Terminated | Bristol-Myers Squibb | 769 | 2022-04-28 | 2026-08-26 |
| Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer Futuximab/modotuximab, Trifluridine/Tipiracil - Metastatic Colorectal Cancer | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 7 | 2022-04-21 | 2024-08-20 |
| Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency synthetic human secretin - Abdominal Pain, Irritable Bowel Syndrome | Phase 3 | Terminated | Orlando Health, Inc. | 27 | 2022-01-28 | 2024-04-03 |
| FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM Irinotecan, Oxaliplatin HAI, Floxuridine - Metastatic Colorectal Cancer, Liver Metastases | Phase 3 | Terminated | Sun Yat-sen University | 92 | 2021-12-31 | 2023-02-16 |
| The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo - Ulcerative Colitis | Phase 3 | Terminated | InDex Pharmaceuticals | 171 | 2021-11-24 | 2023-12-27 |
| A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC SHR-1701、 BP102 、XELOX, placebo、 BP102、 XELOX - Metastatic Colorectal Cancer (mCRC) | Phase 2 / Phase 3 | Terminated | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 62 | 2021-06-22 | 2025-05-18 |
| Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy Valganciclovir - Ulcerative Colitis, Unspecified | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 6 | 2021-04-22 | 2024-04-10 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Trilaciclib, Placebo - Colorectal Cancer Metastatic, Myelosuppression-Adult | Phase 3 | Terminated | G1 Therapeutics, Inc. | 326 | 2021-01-06 | 2024-11-26 |
| Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis Rosuvastatin 10mg - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Universitaire Ziekenhuizen KU Leuven | 177 | 2020-10-22 | 2025-11-25 |
| Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial Sevoflurane, Propofol, Lidocaine IV - Colonic Cancer, Rectal Cancer | Phase 3 | Terminated | Peter MacCallum Cancer Centre, Australia | 254 | 2020-07-31 | 2025-03-14 |
| TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Terminated | Theravance Biopharma | 46 | 2020-07-23 | 2022-11-02 |
| The Role of Secondary Bile Acids in Intestinal Inflammation ursodiol (ursodeoxycholic acid, UDCA) - Ulcerative Colitis, Pouchitis | Phase 2 / Phase 3 | Terminated | Stanford University | 2 | 2019-08-26 | 2026-03-11 |
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer Radiotherapy, oxaliplatin+capecitabine - Colon Cancer | Phase 3 | Terminated | Sun Yat-sen University | 49 | 2019-05-11 | 2022-06-08 |
| Efficacy & Safety of TD-1473 in Ulcerative Colitis TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Terminated | Theravance Biopharma | 239 | 2019-03-11 | 2022-11-15 |
| Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer Calmangafodipir (5 µmol/kg), Placebo - Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy | Phase 3 | Terminated | Egetis Therapeutics AB (publ) | 301 | 2019-01-07 | 2022-01-26 |
| Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg), Placebo - Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy | Phase 3 | Terminated | Egetis Therapeutics AB (publ) | 291 | 2018-11-07 | 2021-12-17 |
Showing 20 of 94. Sign in to see all of them.
Colorectal Neoplasms (43) · Colitis, Ulcerative (30) · Colonic Neoplasms (26) · Rectal Neoplasms (15) · Inflammatory Bowel Diseases (7) · Irritable Bowel Syndrome (6) · Neoplasm Metastasis (5) · Gastrointestinal Diseases (4) · Lung Neoplasms (4) · Breast Neoplasms (3) · Diarrhea (3) · Intestinal Diseases (3) · Ulcer (3) · Adenomatous Polyps (2)
Digestive System Diseases (92) · Intestinal Diseases (91) · Gastrointestinal Diseases (90) · Digestive System Neoplasms (57) · Intestinal Neoplasms (57) · Neoplasms by Site (57) · Gastrointestinal Neoplasms (56) · Neoplasms (56) · Rectal Diseases (48) · Gastroenteritis (31) · Colitis (30) · Inflammatory Bowel Diseases (25) · Pathological Conditions, Signs and Symptoms (22) · Colorectal Neoplasms (14)
Fluorouracil (11) · Leucovorin (11) · Capecitabine (9) · Irinotecan (9) · Oxaliplatin (9) · Bevacizumab (6) · Cetuximab (4) · Celecoxib (3) · Floxuridine (3) · Mesalamine (3) · regorafenib (3) · Andrographis paniculata extract (2) · Aspirin (2) · Azathioprine (2) · IFL protocol (2)
NSABP Foundation Inc (5) · Alliance for Clinical Trials in Oncology (3) · Sun Yat-sen University (3) · Assistance Publique - Hôpitaux de Paris (2) · Auron Healthcare GmbH (2) · Bristol-Myers Squibb (2) · Egetis Therapeutics AB (publ) (2) · Facet Biotech (2) · Hutchison Medipharma Limited (2) · Janssen Research & Development, LLC (2) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (2) · Shire (2) · Swiss Cancer Institute (2)
United States (55) · France (23) · Germany (22) · Italy (20) · Belgium (19) · Hungary (19) · Canada (17) · Poland (17) · United Kingdom (17) · Spain (15) · Australia (14) · Czechia (14) · Israel (13) · Slovakia (13) · Netherlands (12)
Norman Wolmark, MD (5) · Sandro Ardizzone, MD (2) · Stefan Carlsson, MD (2) · Afsaneh Barzi, MD (1) · Ala' I. Sharara, MD (1) · Alan Venook, MD (1) · Alexander Stojadinovic, MD (1) · Alfredo Falcone, MD (1) · Anders Jakobsen, Prof, MDSc (1) · Andres J Yarur, MD (1) · Ara Vaporciyan, MD, BS (1)
PMID 36308441, PMID 40013523, PMID 18378608, PMID 20937118, PMID 20947884, PMID 21890814, PMID 23060037, PMID 24512909, PMID 25600568, PMID 25605741, PMID 26119226, PMID 28627732, PMID 28917648, PMID 30899530, PMID 31982148, PMID 32079623, PMID 32143730, PMID 32445184, PMID 35815403, PMID 37806372, PMID 39364270, PMID 39579142, PMID 39644535, PMID 39676137
2017 (3), 2018 (2), U10CA032102 (2), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2019 (1), K23CA115908 (1), P01CA041108 (1), P30CA014089 (1), P30CA023074 (1), U01CA079778 (1), U01CA080098 (1), U10CA012027 (1)